Beneficial effects of omega-3 fatty acids in the proteome of high-density lipoprotein proteome

Lipids in Health and Disease

Volumn 11, Issue , 2012, Pages

  Burillo, Elena ^a,c   Mateo Gallego, Rocío ^a,c   Cenarro, Ana ^a,c   Fiddyment, Sarah ^a,c   Bea, Ana M ^a,c   Jorge, Inmaculada ^b,c   Vázquez, Jesús ^b,c   Civeira, Fernando ^a,c  

^a INSTITUTO DE INVESTIGACIÓN SANITARIA ARAGÓN IIS ARAGÓN   (Spain)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Cardiovascular risk; HDL proteome; Omega 3 poly unsaturated fatty acids

Indexed keywords

ALPHA 1 ANTITRYPSIN; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; CLUSTERIN; COMPLEMENT COMPONENT C1R; COMPLEMENT FACTOR H; FIBRONECTIN; HAPTOGLOBIN RELATED PROTEIN; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN KAPPA CHAIN; OMEGA 3 FATTY ACID; PROTEOME; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SEQUENCE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BIOCHEMISTRY; CARDIOVASCULAR RISK; CLINICAL ARTICLE; DIET SUPPLEMENTATION; HEART PROTECTION; HUMAN; IMMUNODETECTION; MALE; PROTEIN EXPRESSION; PROTEOMICS; SMOKING; UPREGULATION;

ADULT; APOLIPOPROTEIN A-I; ARYLDIALKYLPHOSPHATASE; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CHROMATOGRAPHY, AFFINITY; CLUSTERIN; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PROTEOME; SMOKING;

EID: 84866149822     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-11-116     Document Type: Article

References (36)

1. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ, Atherosclerosis 2008 197 12 24 10.1016/j.atherosclerosis.2007.11.008 18160071
2. The mechanisms of action of PPARs. Berger J, Moller DM, Annu Rev Med 2002 53 409 435 10.1146/annurev.med.53.082901.104018 11818483 (Pubitemid 34177889)
3. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. Siscovick DS, Raghunathan TE, King I, Weinmann S, Wicklund KG, Albright J, et al. JAMA 1995 274 1363 1367 10.1001/jama.1995.03530170043030 7563561
4. An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. Calabresi L, Villa B, Canavesi M, Sirtori CR, James RW, Bernini F, et al. Metabolism 2004 53 153 158 10.1016/j.metabol.2003. 09.007 14767865 (Pubitemid 38168885)
5. Fatty acid modulation of endothelial activation. De Caterina R, Liao JK, Libby P, Am J Clin Nutr 2000 71 213S 223S 10617974 (Pubitemid 30046119)
6. Importance of n-3 fatty acids in health and disease. Connor WE, Am J Clin Nutr 2000 71 171S 175S 10617967 (Pubitemid 30046112)
7. Omega-3 fatty acids and cardiovascular disease: a case for omega-3 index as a new risk factor. Harris WS, Pharmacol Res 2007 55 217 223 10.1016/j.phrs.2007.01.013 17324586 (Pubitemid 46518155)
8. Endothelial and antithrombotic actions of HDL. Mineo C, Deguchi H, Griffin J, Shaul P, Circ Res 2006 98 1352 1364 10.1161/01.RES.0000225982.01988. 93 16763172 (Pubitemid 43948059)
9. Antiinflammatory properties of HDL. Barter P, Nicholls S, Rye K, Anantharamaiah G, Navab M, Fogelman A, Circ Res 2004 95 764 772 10.1161/01.RES.0000146094.59640.13 15486323 (Pubitemid 39390578)
10. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. Navab M, Hama S, Cooke C, Anantharamaiah G, Chaddha M, Jin L, et al. J Lipid Res 2000 41 1481 1494 10974056
11. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. Navab M, Hama S, Anantharamaiah G, Hassan K, Hough G, Watson A, et al. J Lipid Res 2000 41 1495 1508 10974057
12. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. Vaisar T, Pennathur S, Green P, Gharib S, Hoofnagle A, Cheung M, et al. J Clin Invest 2007 117 746 756 10.1172/JCI26206 17332893 (Pubitemid 46348533)
13. Molecular regulation of HDL metabolism and function: implications for novel therapies. Rader D, J Clin Invest 2006 116 3090 3100 10.1172/JCI30163 17143322 (Pubitemid 44878620)
14. Smoking induces lipoprotein-associated phospholipase A2 in cardiovascular disease free adults: the ATTICA Study. Tselepis AD, Panagiotakos DB, Pitsavos C, Tellis CC, Chrysohoou C, Stefanadis C, Atherosclerosis 2009 206 303 308 10.1016/j.atherosclerosis.2009.02.016 19394616
15. Fish intake may limit the increase in risk of coronary heart disease morbidity and mortality among heavy smokers. The Honolulu Heart Program. Rodriguez BL, Sharp DS, Abbott RD, Burchfiel CM, Masaki K, Chyou PH, et al. Circulation 1996 94 952 956 10.1161/01.CIR.94.5.952 8790031 (Pubitemid 26292846)
16. Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials. Filion KB, El Khoury F, Bielinski M, Schiller I, Dendukuri N, Brophy JM, BMC Cardiovasc Disord 2010 10 24 10.1186/1471-2261- 10-24 20525225
17. Fish oil and arrhythmias. Pro-arrhythmic effects of fish oils. Saravanan P, Davidson NC, BMJ 2009 338 393 10.1136/bmj.b393 19188223
18. Cardiovascular effects of marine omega-3 fatty acids. Saravanan P, Davidson NC, Schmidt EB, Calder PC, Lancet 2010 376 540 550 10.1016/S0140- 6736(10)60445-X 20638121
19. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential. Ribas V, Sánchez-Quesada JL, Antán R, Camacho M, Julve J, Escol-Gil JC, et al. Circ Res 2004 95 789 797 10.1161/01.RES.0000146031.94850.5f 15388641 (Pubitemid 39390581)
20. An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Wagner AC, Hama S, et al. Arterioscler Thromb Vasc Biol 2005 25 1932 1937 10.1161/01.ATV.0000174589.70190. e2 15961700 (Pubitemid 41243465)
21. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. Tall A, J Intern Med 2008 263 256-3
22. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, Reddy ST, Sevanian A, Fonarow GC, Fogelman AM, J Lipid Res 2000 Sep 41 9 1495 1508
23. Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. Garner B, Waldeck AR, Witting PK, Rye KA, Stocker R, J Biol Chem 1998 273 11 6088 10.1074/jbc.273.11.6088 9497326 (Pubitemid 28144688)
24. Apolipoprotein E-dependent cholesterol efflux from macrophages: kinetic study and divergent mechanisms for endogenous versus exogenous apolipoprotein E. Lin CY, Duan H, Mazzone T, J Lipid Res 1999 40 1618 1627 10484608
25. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Zheng C, Khoo C, Furtado J, Sacks FM, Circulation 2010 121 1722 1734 10.1161/CIRCULATIONAHA.109.875807 20368524
26. Uremia Alters HDL Composition and Function. Holzer M, Birner-Gruenberger R, Stojakovic T, El-Gamal D, Binder V, Wadsack C, Heinemann A, Marsche G, J Am Soc Nephrol 2011 22 9 1631 1641 Epub 2011 Jul 29 10.1681/ASN.2010111144 21804091
27. Complement activation by cigarette smoke. Robbins RA, Nelson KJ, Gossman GL, Koyama S, Rennard SI, Am J Physiol 1991 260 254 L259 1902064
28. Interaction between apolipoproteins A-I and A-II and the membrane attack complex of complement. Affinity of the apoproteins for polymeric C9. Hamilton KK, Zhao J, Sims PJ, J Biol Chem 1993 268 3632 3638 8429039 (Pubitemid 23071007)
29. Nicotine and fibronectin expression in lung fibroblasts: implications for tobacco-related lung tissue remodeling. Roman J, Ritzenthaler JD, Gil-Acosta A, Rivera HN, Roser-Page S, FASEB J 2004 18 1436 1438 15247149 (Pubitemid 39561606)
30. Acute cigarette smoke-induced connective tissue breakdown is mediated by neutrophils and prevented by alpha1-antitrypsin. Dhami R, Gilks B, Xie C, Zay K, Wright JL, Churg A, Am J Respir Cell Mol Biol 2000 22 244 252 10657946 (Pubitemid 30351488)
31. Identification of potential serum biomarkers of inflammation and lipid modulation that are altered by fish oil supplementation in healthy volunteers. de Roos B, Geelen A, Ross K, Rucklidge G, Reid M, Duncan G, et al. Proteomics 2008 8 1965 1974 10.1002/pmic.200700457 18491311 (Pubitemid 351775776)
32. Proteomic analysis of human plasma and blood cells in nutritional studies: development of biomarkers to aid disease prevention. de Roos B, Expert Rev Proteomics 2008 5 819 826 10.1586/14789450.5.6.819 19086861
33. Nutrition proteomics and biomarker discovery. de Roos B, Expert Rev Proteomics 2009 6 349 351 10.1586/epr.09.52 19681670
34. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Friedewald W, Levy R, Fredrickson D, Clin Chem 1972 18 499 502 4337382
35. Reproducibility of an FFQ validated in Spain. de la Fuente-Arrillaga C, Ruiz ZV, Bes-Rastrollo M, Sampson L, Martinez-González MA, Public Health Nutr 2010 13 1364 1372 10.1017/S1368980009993065 20105389
36. Validation of the Minnesota Leisure Time Physical Activity Questionnaire in Spanish men. The MARATHOM Investigators. Elosua R, Marrugat J, Molina L, Pons S, Pujol E, Am J Epidemiol 1994 139 1197 1209 8209878 (Pubitemid 24184413)